Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations
Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations
Active, not recruiting · NCT04695925 · Registry updated 2025-10-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations | EGFR Gene Mutation; Non-small Cell Carcinoma | Active, not recruiting | Phase 3 | 2025-10-15 | NCT04695925 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cancer Hospital of Guangxi Medical University | 22 |
| First People's Hospital of Foshan | 44 |
| Henan Cancer Hospital | 147 |
| Li Zhang, MD | 2 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Central Hospital of Guangdong Nongken, Zhanjiang Cancer Hospital | Zhanjiang | China | 1 |
| Department of Medical Oncology,Cancer Center of Sun Yat-Sen University | Guangzhou | China | 2 |